EU Tackles Counterfeits, But Parallel Trade Poses Tough Issues
Tackling counterfeit drugs is one pillar of the European Commission's package of new proposed pharmaceutical legislation. It will mean higher costs for most drug firms, while significant loopholes will remain
You may also be interested in...
A German court ruling should protect high-cost original product drugs from being split by re-packagers and sold in smaller batches for profit.
Greece's debt woes lead to cuts in pharmaceutical prices and fears of an increase in parallel trade
Patient rights to access information on prescription drugs could mean that industry should be permitted to provide data, says a draft EU report.